Core Viewpoint - Lai Kai Pharmaceutical (2105.HK) experienced a significant increase of over 18%, reaching a peak of 16.72 HKD, marking a new high in over a month following the announcement of its new drug LAE118, which has been accepted for clinical trial application by the FDA [1] Group 1 - The new drug LAE118 is designed to treat PIK3CA mutation-related solid tumors, representing a novel therapy in this area [1] - LAE118 is characterized as a novel PI3Kα pan-mutant selective inhibitor, targeting PIK3CA mutated solid tumors [1] - The company plans to work closely with regulatory authorities to complete the relevant application process for LAE118 [1] Group 2 - The company has a proven track record in clinical development and licensing with LAE002 (afuresertib), which enhances its credibility in providing new treatment options [1] - Lai Kai Pharmaceutical is committed to offering precision treatments for cancer patients in need of new therapeutic solutions [1]
港股异动｜来凯医药大涨超18%，旗下新药LAE118临床试验申请获美国FDA受理